Whether adagrasib (Krazati) can be vaccinated and what precautions should be taken during vaccination

Adagrasiib (Krazati) is an oral KRAS G12C inhibitor mainly used for the treatment of patients with advanced or metastatic non-small cell lung cancer. With the popularity of targeted therapy, more and more patients are concerned about whether they can receive vaccines during medication, especially influenza vaccines, COVID-19 vaccines or other conventional vaccines. For the use of adagrasib, vaccination needs to comprehensively consider the impact of the drug on the immune system, the patient's overall physical condition, and the potential risk of adverse reactions.

First of all, from the perspective of pharmacological effects, adagrasib is a highly selective KRAS G12C inhibitor that mainly acts on the signaling pathways of tumor cells and has relatively limited direct inhibitory effects on the human immune system. Therefore, in theory, adagrasib will not significantly weaken the immune response like chemotherapy or certain immunosuppressive drugs. However, patients may be accompanied by tumor burden, decreased immune function, or other underlying diseases during long-term medication. These factors may affect the immune response after vaccination.

In clinical practice, administration of inactivated vaccines is generally considered safe in patients receiving adagrasib. For example, influenza vaccine, inactivated COVID-19 vaccine or pneumococcal polysaccharide vaccine. These vaccines do not contain live viruses and generally will not cause infectious diseases after vaccination. At the same time, they can stimulate the body to produce a certain level of antibodies and improve the patient's ability to resist infection. Before receiving the vaccine, patients should inform their doctor that they are using adagrasib, so that the doctor can evaluate their physical condition and possibility of immune response, and arrange the vaccination time appropriately.

For live vaccines, such as attenuated chickenpox vaccine, measles-mumps-rubella (MMR) live vaccine, etc., you need to consider carefully. Although adagrasib is not a traditional immunosuppressive drug, the immune function of patients with advanced cancer may not be completely normal, and there is a risk of infection when receiving live vaccines. Therefore, it is generally recommended to weigh the pros and cons after a doctor's evaluation, postpone vaccination if necessary, or choose an inactivated vaccine instead.

Timing of vaccination is also very important. It is recommended that vaccination be given before or between treatments with adagrasiib to allow the body enough time to mount an immune response. If a patient is experiencing drug-related adverse reactions, such as abnormal liver function, decreased blood parameters, or significant fatigue, it is best to postpone vaccination until symptoms stabilize. After vaccination, patients should closely observe physical reactions. If they experience high fever, general fatigue, severe local redness and swelling, or allergic reactions, they should contact their doctor in time.

In addition, patients who receive vaccines during medication should also pay attention to interactions with other drugs. Some supportive care drugs or adjuvant drugs may affect the immune response, such as glucocorticoids, immunosuppressants, or certain anti-infective drugs. If such drugs are used at the same time, the medication regimen should be adjusted reasonably under the guidance of a doctor to ensure that vaccination is both safe and effective.

In general, it is feasible and relatively safe to administer inactivated vaccines during adagrasib treatment, while live vaccines need to be carefully evaluated. Before vaccination, patients should inform their doctors in detail about their medication status, underlying diseases and recent physical conditions, and follow the doctor's guidance to arrange vaccination time and dosage. After vaccination, the body's reaction should be closely observed, and the immune effect should be evaluated in conjunction with regular reexaminations. Through scientific arrangements and reasonable monitoring, while ensuring anti-tumor treatment, adagrasib patients can also effectively obtain vaccine protection and improve their overall health.

Reference materials:https://www.drugs.com/